Loading people...
George C. Petrocheilos is the Co-Founder and Managing Partner of Catalio Capital Management, a life sciences investment firm based in New York and Baltimore. Under his co-leadership, the firm has grown to manage over $1 billion in assets, including the $381 million Nexus III venture fund, and sold a minority stake to KKR in 2023. Previously, he served as a General Partner at Camden Partners, a firm spun out of T. Rowe Price, and was President of the NASDAQ-listed HealthCor Catalio Special Purpose Acquisition Corp. He has held board positions at several biotechnology companies, including Haystack Oncology, which was acquired by Quest Diagnostics, alongside Octant Bio and DNA Script. After earning a Bachelor of Arts degree in financial economics from Johns Hopkins University, his career has remained focused on investing in private breakthrough biomedical technology companies.
George C. Petrocheilos stands as a prominent figure in the healthcare investment landscape, serving as a Managing Partner and co-founder of Catalio Capital. His leadership has been crucial in establishing Catalio as a multi-strategy firm dedicated to advancing medical innovation through strategic capital deployment. Petrocheilos brings a unique blend of entrepreneurial drive, deep industry knowledge, and a commitment to fostering companies that address critical unmet medical needs.
At Catalio Capital, George C. Petrocheilos is at the forefront of identifying and supporting transformative companies across various stages of development. Catalio Capital's mission is to bridge the gap between groundbreaking scientific research and commercial success, a vision that Petrocheilos passionately champions. He is deeply involved in all aspects of the firm's investment strategy, from deal sourcing and due diligence to portfolio management and value creation. His work ensures that Catalio invests in ventures poised to make a significant impact on global health.
Petrocheilos's investment focus spans the breadth of the healthcare and life sciences sectors. This includes cutting-edge biotechnology, innovative medical devices, advanced diagnostics, and disruptive digital health solutions. A key area of interest for him is companies emerging from leading academic institutions, particularly those with strong intellectual property and a clear path to commercialization. He seeks out opportunities where scientific rigor meets market potential, aiming to accelerate the development of therapies and technologies that improve patient outcomes.
Before co-founding Catalio Capital, George C. Petrocheilos built a distinguished career marked by entrepreneurial success and significant contributions to the healthcare industry. He previously co-founded and served as CEO of a medical technology company, gaining firsthand experience in bringing innovative products to market. This entrepreneurial journey provided him with invaluable insights into the challenges and opportunities faced by early-stage healthcare ventures. His background also includes experience in investment banking and private equity, equipping him with a comprehensive understanding of financial markets and strategic growth. Petrocheilos maintains strong ties to academic institutions, notably Johns Hopkins University, where he has served on various boards and councils, further solidifying his connection to the scientific community.
Through his work at Catalio Capital, George C. Petrocheilos is not merely investing capital; he is investing in the future of medicine. His vision is to cultivate a portfolio of companies that not only deliver strong financial returns but also drive meaningful advancements in healthcare. By leveraging his extensive network and expertise, he empowers founders and scientists to translate their discoveries into tangible solutions that benefit patients worldwide. His strategic approach and unwavering dedication position him as a key influencer in shaping the next generation of healthcare innovation.
George C. Petrocheilos is a co-founder and Managing Partner of Catalio Capital, a multi-strategy healthcare investment firm. He is a prominent investor and entrepreneur known for his expertise in life sciences, biotechnology, and medical technology, driving innovation from academic research to commercial success.
George C. Petrocheilos invests in a broad range of healthcare and life sciences sectors. His focus areas include biotechnology, medical devices, diagnostics, and digital health solutions. He particularly targets companies with strong scientific foundations, often emerging from leading academic institutions, that have the potential to address significant unmet medical needs.
George C. Petrocheilos works as a Managing Partner at Catalio Capital. Catalio Capital is a multi-strategy healthcare investment firm with offices in New York City and Baltimore, Maryland, reflecting its strong ties to major financial and academic healthcare hubs.
